Clinical trial · Observational
Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer
Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.
NCT01647555CI-TRIAL-00105886completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the skin toxicities in patients with epidermoid cancer, treated by Radiotherapy in association with Cetuximab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epidermoid Head and Neck Cancer | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Drug | Cetuximab | ALIAS |
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patient with epidermoid cancer
- description
- receiving Cetuximab and radiotherapy
- interventionNames
- Drug: Cetuximab
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Skin toxicities
- timeFrame
- until week 38
- description
- according to NCI-CTCAE version 3.0
Secondary outcomes (3)
- measure
- Healthcare and evolution of skin toxicities
- timeFrame
- until week 38
- description
- Treatment of skin toxicities, according to sponsor advices.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Epidermoid head and neck carcinoma locally advanced * Indication of Cetuximab and radiotherapy * Karnofsky \>= 60 * Patients participating to another compatible study could be included after consultation with the study director Patients could be beforehand treated for an other ORL cancer The radiotherapy will be delivered for curative aim (minimal dose 66 Gy) Exclusion Criteria: * other histology * Metastatic disease * Recurrent patients
References
Publications (0)
Data not yet available
No reference posted for this study.